-
公开(公告)号:US20180207285A1
公开(公告)日:2018-07-26
申请号:US15880101
申请日:2018-01-25
发明人: Yanwen Fu , Gunnar F. Kaufmann
摘要: Provided are compounds having the Formula I or II: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancers.
-
公开(公告)号:US20180194859A1
公开(公告)日:2018-07-12
申请号:US15870830
申请日:2018-01-12
发明人: Gunnar F. Kaufmann , Yanwen Fu , James Patterson , Tong Zhu
IPC分类号: C07K16/46
CPC分类号: C07K16/46 , A61K2039/505 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/53 , C07K2317/54 , C07K2317/92
摘要: There is disclosed methods for derivatizing and conjugating two hinge-containing antibody molecules. There is further disclosed derivatized and conjugated hinge-containing antibody molecules.
-
公开(公告)号:US09631009B2
公开(公告)日:2017-04-25
申请号:US14473916
申请日:2014-08-29
发明人: Gunnar F. Kaufmann , Heyue Zhou , Guodi Lu
CPC分类号: C07K16/1271 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要: There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments and derivatives of such antibodies, and AIP2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having AIP2 related disorders or conditions. There is also disclosed a method to treat S. aureus infections by administering an anti-AIP2 antibody described herein.
-
公开(公告)号:US20220144971A1
公开(公告)日:2022-05-12
申请号:US17585378
申请日:2022-01-26
摘要: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.
-
公开(公告)号:US20210138075A1
公开(公告)日:2021-05-13
申请号:US17153655
申请日:2021-01-20
发明人: Yanwen Fu , Gunnar F. Kaufmann , Heehyoung Lee , Tong Zhu , Henry Hongjun Ji
IPC分类号: A61K47/58 , A61K47/59 , A61K31/365 , C07K16/18
摘要: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
-
公开(公告)号:US10472413B2
公开(公告)日:2019-11-12
申请号:US15462427
申请日:2017-03-17
发明人: Gunnar F. Kaufmann , Heyue Zhou , Guodi Lu
摘要: There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments and derivatives of such antibodies, and AIP2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having AIP2 related disorders or conditions. There is also disclosed a method to treat S. aureus infections by administering an anti-AIP2 antibody described herein.
-
公开(公告)号:US20190038764A1
公开(公告)日:2019-02-07
申请号:US16052406
申请日:2018-08-01
发明人: James T. Patterson , Gunnar F. Kaufmann , Yanwen Fu , Tong Zhu
IPC分类号: A61K47/68
CPC分类号: A61K47/6851 , A61K47/55 , A61K47/6849
摘要: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
-
公开(公告)号:US20170313776A1
公开(公告)日:2017-11-02
申请号:US15589051
申请日:2017-05-08
IPC分类号: C07K16/28
摘要: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
-
公开(公告)号:US09676853B2
公开(公告)日:2017-06-13
申请号:US14292866
申请日:2014-05-31
IPC分类号: C07K16/28 , A61K39/395
CPC分类号: C07K16/2818 , C07K2317/21 , C07K2317/33 , C07K2317/622 , C07K2317/70 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
-
公开(公告)号:US20240197881A1
公开(公告)日:2024-06-20
申请号:US18287255
申请日:2022-04-22
发明人: Henry Hongjun Ji , Wenzhong Guo , Yanliang Zhang , Bei Bei Ding , Yang Wang , Gunnar F. Kaufmann
IPC分类号: A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/30 , C12N5/0783
CPC分类号: A61K39/464471 , A61K39/4611 , A61K39/4631 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/3084 , C12N5/0636 , C07K2319/03 , C12N2510/00
摘要: The present disclosure provides transgenic T cells expressing engineered dimeric antigen receptors (DARs) that bind GD2. where the DAR includes a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The transgenic T cells can be used for directed cell therapy.
-
-
-
-
-
-
-
-
-